LT2593131T - Būdai ir kompozicijos, skirti iduronato 2-sulfatazės pristatymui į cns - Google Patents
Būdai ir kompozicijos, skirti iduronato 2-sulfatazės pristatymui į cnsInfo
- Publication number
- LT2593131T LT2593131T LT11799036T LT11799036T LT2593131T LT 2593131 T LT2593131 T LT 2593131T LT 11799036 T LT11799036 T LT 11799036T LT 11799036 T LT11799036 T LT 11799036T LT 2593131 T LT2593131 T LT 2593131T
- Authority
- LT
- Lithuania
- Prior art keywords
- iduronate
- sulfatase
- compositions
- methods
- cns delivery
- Prior art date
Links
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 title 1
- 101710096421 Iduronate 2-sulfatase Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35885710P | 2010-06-25 | 2010-06-25 | |
US36078610P | 2010-07-01 | 2010-07-01 | |
US38786210P | 2010-09-29 | 2010-09-29 | |
US201161435710P | 2011-01-24 | 2011-01-24 | |
US201161442115P | 2011-02-11 | 2011-02-11 | |
US201161476210P | 2011-04-15 | 2011-04-15 | |
US201161495268P | 2011-06-09 | 2011-06-09 | |
PCT/US2011/041925 WO2011163649A2 (en) | 2010-06-25 | 2011-06-25 | Methods and compositions for cns delivery of iduronate-2-sulfatase |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2593131T true LT2593131T (lt) | 2019-10-25 |
Family
ID=46888843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LT11799036T LT2593131T (lt) | 2010-06-25 | 2011-06-25 | Būdai ir kompozicijos, skirti iduronato 2-sulfatazės pristatymui į cns |
Country Status (24)
Country | Link |
---|---|
US (1) | US8545837B2 (lt) |
EP (3) | EP3964229A1 (lt) |
JP (1) | JP6045492B2 (lt) |
KR (5) | KR102356192B1 (lt) |
CN (1) | CN103179980B (lt) |
AU (4) | AU2011270669B2 (lt) |
CA (1) | CA2805448A1 (lt) |
CY (2) | CY1122307T1 (lt) |
DK (1) | DK2593131T3 (lt) |
ES (1) | ES2754234T3 (lt) |
HR (1) | HRP20191924T1 (lt) |
IL (3) | IL284599B2 (lt) |
LT (1) | LT2593131T (lt) |
ME (1) | ME03649B (lt) |
MX (2) | MX2013000322A (lt) |
NZ (2) | NZ702808A (lt) |
PL (2) | PL3626258T3 (lt) |
RS (1) | RS59469B1 (lt) |
RU (1) | RU2660348C2 (lt) |
SI (1) | SI2593131T1 (lt) |
TW (1) | TWI611808B (lt) |
UA (1) | UA115649C2 (lt) |
WO (1) | WO2011163649A2 (lt) |
ZA (1) | ZA201300672B (lt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003222568B2 (en) | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
JP5901877B2 (ja) | 2007-07-27 | 2016-04-13 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | 中枢神経系のα−L−イデュロニダーゼ活性を増加させるための方法および組成物 |
PT3626258T (pt) | 2010-06-25 | 2021-10-19 | Shire Human Genetic Therapies | Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase |
PL3626257T3 (pl) | 2010-06-25 | 2022-03-28 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania arylosulfatazy a do oun |
RU2626514C2 (ru) | 2010-06-25 | 2017-07-28 | Шир Хьюман Дженетик Терапис, Инк. | Доставка к цнс лечебных агентов |
US9320711B2 (en) * | 2010-06-25 | 2016-04-26 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of heparan N-sulfatase |
WO2011163649A2 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc | Methods and compositions for cns delivery of iduronate-2-sulfatase |
US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
PL2717917T3 (pl) | 2011-07-05 | 2016-12-30 | Koniugaty p97 - przeciwciało | |
EP2793922B1 (en) | 2011-12-23 | 2019-10-30 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
WO2013096912A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase |
CA2868466A1 (en) | 2012-03-30 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate-2-sulfatase |
KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
US20140004097A1 (en) | 2012-06-29 | 2014-01-02 | Shire Human Genetic Therapies, Inc. | Method of producing recombinant iduronate-2-sulfatase |
JP6433424B2 (ja) * | 2012-07-31 | 2018-12-05 | バイオアシス テクノロジーズ インコーポレイテッド | 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法 |
EA039246B1 (ru) * | 2012-12-06 | 2021-12-22 | Шир Хьюман Дженетик Терапис, Инк. | Способ лечения когнитивных нарушений, связанных с синдромом хантера |
BR112015022416A2 (pt) | 2013-03-13 | 2017-10-24 | Bioasis Technologies Inc | fragmentos de p97 e seus usos |
CA2912678C (en) * | 2013-05-15 | 2023-10-10 | Regents Of The University Of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
US20160347821A1 (en) | 2014-02-03 | 2016-12-01 | Bioasis Technologies, Inc. | P97 fusion proteins |
ES2762672T3 (es) | 2014-02-19 | 2020-05-25 | Bioasis Technologies Inc | Proteínas de fusión de P97-IDS |
JP6847664B2 (ja) | 2014-05-01 | 2021-03-24 | バイオアシス テクノロジーズ インコーポレイテッド | P97−ポリヌクレオチド複合体 |
MA40954A (fr) | 2014-11-14 | 2017-09-19 | Shire Human Genetic Therapies | Détermination de niveaux de glycosaminoglycane par spectrométrie de masse |
EP3292206B8 (en) | 2015-05-07 | 2022-02-09 | Takeda Pharmaceutical Company Limited | Glucocerebrosidase gene therapy for parkinson's disease |
HUE057795T2 (hu) * | 2015-05-15 | 2022-06-28 | Regenxbio Inc | Adenoasszociált vírus terápiás szerek központi idegrendszerbe történõ bejuttatására |
KR20170004814A (ko) | 2015-07-02 | 2017-01-11 | 주식회사 녹십자 | 헌터증후군 치료제 |
WO2017003270A1 (ko) * | 2015-07-02 | 2017-01-05 | 주식회사 녹십자 | 헌터증후군 치료제 및 치료방법 |
DK3397270T3 (da) * | 2015-12-30 | 2024-05-06 | Green Cross Corp | Sammensætninger til anvendelse i behandlingen af hunters syndrom |
SG11201805680SA (en) * | 2016-01-15 | 2018-07-30 | Sangamo Therapeutics Inc | Methods and compositions for the treatment of neurologic disease |
BR112018016874A2 (pt) * | 2016-02-17 | 2019-02-05 | Shire Human Genetic Therapies | métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc) |
JP7109369B2 (ja) * | 2016-02-24 | 2022-07-29 | バイオマリン ファーマシューティカル インコーポレイテッド | ターゲティングされた治療用リソソーム酵素融合タンパク質、関連する製剤、およびその使用 |
KR20230125339A (ko) | 2016-04-15 | 2023-08-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ii형 점액다당류증의 치료를 위한 유전자 요법 |
BR112019013202A2 (pt) | 2016-12-28 | 2019-12-10 | Japan Chem Res | formulação liofilizada |
IL307936A (en) | 2017-04-14 | 2023-12-01 | Regenxbio Inc | Treatment for mucopolysaccharidosis 2 with the help of recombinant human iduronate-2 suplatase (ids) produced by human neuron or glial cells |
BR112020005249A2 (pt) | 2017-09-22 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | terapia de gene para tratar mucopolissacaridose tipo ii |
JP2021500857A (ja) | 2017-10-02 | 2021-01-14 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 酵素補充療法用酵素を含む融合タンパク質 |
JP7060235B2 (ja) * | 2018-05-18 | 2022-04-26 | 国立大学法人広島大学 | 変異型イズロン酸-2-スルファターゼの機能回復薬剤のスクリーニング方法 |
KR102671857B1 (ko) * | 2018-05-30 | 2024-06-04 | 주식회사 녹십자 | 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물 |
EP3811962A4 (en) | 2018-06-25 | 2022-03-16 | JCR Pharmaceuticals Co., Ltd. | PROTEIN AQUEOUS LIQUID FORMULATION |
KR20200047937A (ko) * | 2018-10-26 | 2020-05-08 | 재단법인 목암생명과학연구소 | Ids를 포함하는 융합 단백질 및 이의 용도 |
US20220002688A1 (en) | 2018-12-20 | 2022-01-06 | Armagen, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
KR20230145386A (ko) | 2021-02-10 | 2023-10-17 | 리젠엑스바이오 인크. | 재조합 인간 이두로네이트-2-설파타아제(ids)를 사용한 점액다당류증 ii의 치료 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
DK0900569T3 (da) * | 1997-08-22 | 2003-01-27 | Seikagaku Kogyo Co Ltd | Terapeutisk middel til behandling af herniaramt intervertebral diskus |
ES2312222T3 (es) | 1998-12-07 | 2009-02-16 | Genzyme Corporation | Tratamiento de la enfermedad de pompe. |
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US6642038B1 (en) | 1999-09-14 | 2003-11-04 | Genzyme Glycobiology Research Institute, Inc. | GlcNAc phosphotransferase of the lysosomal targeting pathway |
US20020099025A1 (en) * | 1999-12-30 | 2002-07-25 | Heywood James A. | Treatment of neurological disorders |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
ES2300439T3 (es) | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
EP1503788B1 (en) | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
AU2003237314B2 (en) | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
HUE033381T2 (en) * | 2003-01-31 | 2017-11-28 | Mount Sinai School Of Medicine Of New York Univ | Combination therapy for the treatment of protein deficiency disorders |
US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
WO2005074888A2 (en) | 2004-02-03 | 2005-08-18 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
JP2007523648A (ja) | 2004-02-06 | 2007-08-23 | バイオマリン ファーマシューティカル インコーポレイテッド | 高リン酸化リソソーム酵素製剤及びそれらの使用 |
DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
US20050208090A1 (en) | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
JPWO2006121199A1 (ja) | 2005-05-11 | 2008-12-18 | 日本ケミカルリサーチ株式会社 | 脂質小胞体組成物 |
AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
GB0611463D0 (en) | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
WO2008109677A2 (en) | 2007-03-06 | 2008-09-12 | Saint Louis University | Modified enzyme and treatment method |
NZ602498A (en) * | 2007-11-30 | 2014-08-29 | Abbvie Inc | Protein formulations and methods of making same |
US7722865B2 (en) | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
ES2830350T3 (es) | 2008-05-07 | 2021-06-03 | Biomarin Pharm Inc | Péptidos de dirección lisosómica y usos de los mismos |
WO2011163651A2 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE |
US9320711B2 (en) | 2010-06-25 | 2016-04-26 | Shire Human Genetic Therapies, Inc. | Methods and compositions for CNS delivery of heparan N-sulfatase |
PL3626257T3 (pl) | 2010-06-25 | 2022-03-28 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania arylosulfatazy a do oun |
RU2626514C2 (ru) | 2010-06-25 | 2017-07-28 | Шир Хьюман Дженетик Терапис, Инк. | Доставка к цнс лечебных агентов |
WO2011163649A2 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc | Methods and compositions for cns delivery of iduronate-2-sulfatase |
JP2012062312A (ja) * | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
-
2011
- 2011-06-25 WO PCT/US2011/041925 patent/WO2011163649A2/en active Application Filing
- 2011-06-25 RS RSP20191356 patent/RS59469B1/sr unknown
- 2011-06-25 PL PL19192679T patent/PL3626258T3/pl unknown
- 2011-06-25 MX MX2013000322A patent/MX2013000322A/es active IP Right Grant
- 2011-06-25 EP EP21188176.8A patent/EP3964229A1/en active Pending
- 2011-06-25 EP EP11799036.6A patent/EP2593131B1/en active Active
- 2011-06-25 KR KR1020207024827A patent/KR102356192B1/ko active IP Right Grant
- 2011-06-25 PL PL11799036T patent/PL2593131T3/pl unknown
- 2011-06-25 KR KR1020197001325A patent/KR102151889B1/ko active Application Filing
- 2011-06-25 JP JP2013516845A patent/JP6045492B2/ja active Active
- 2011-06-25 RU RU2012154575A patent/RU2660348C2/ru active
- 2011-06-25 CA CA2805448A patent/CA2805448A1/en not_active Abandoned
- 2011-06-25 CN CN201180040898.XA patent/CN103179980B/zh active Active
- 2011-06-25 KR KR1020137001749A patent/KR20130043165A/ko active Application Filing
- 2011-06-25 UA UAA201214667A patent/UA115649C2/uk unknown
- 2011-06-25 KR KR1020237039076A patent/KR20230159646A/ko not_active Application Discontinuation
- 2011-06-25 EP EP19192679.9A patent/EP3626258B1/en active Active
- 2011-06-25 LT LT11799036T patent/LT2593131T/lt unknown
- 2011-06-25 ES ES11799036T patent/ES2754234T3/es active Active
- 2011-06-25 MX MX2020001395A patent/MX2020001395A/es unknown
- 2011-06-25 NZ NZ702808A patent/NZ702808A/en unknown
- 2011-06-25 ME MEP-2019-300A patent/ME03649B/me unknown
- 2011-06-25 NZ NZ605863A patent/NZ605863A/en unknown
- 2011-06-25 KR KR1020227002252A patent/KR102603430B1/ko active IP Right Grant
- 2011-06-25 US US13/168,966 patent/US8545837B2/en active Active
- 2011-06-25 IL IL284599A patent/IL284599B2/en unknown
- 2011-06-25 SI SI201131775T patent/SI2593131T1/sl unknown
- 2011-06-25 AU AU2011270669A patent/AU2011270669B2/en active Active
- 2011-06-25 DK DK11799036.6T patent/DK2593131T3/da active
- 2011-06-27 TW TW100122531A patent/TWI611808B/zh active
-
2012
- 2012-12-18 IL IL223716A patent/IL223716B/en active IP Right Grant
-
2013
- 2013-01-25 ZA ZA2013/00672A patent/ZA201300672B/en unknown
-
2017
- 2017-04-04 AU AU2017202219A patent/AU2017202219B2/en active Active
-
2019
- 2019-05-20 AU AU2019203515A patent/AU2019203515B2/en active Active
- 2019-07-15 IL IL268085A patent/IL268085B/en unknown
- 2019-10-22 HR HRP20191924TT patent/HRP20191924T1/hr unknown
- 2019-11-19 CY CY20191101211T patent/CY1122307T1/el unknown
-
2021
- 2021-04-27 AU AU2021202579A patent/AU2021202579B2/en active Active
- 2021-10-20 CY CY20211100914T patent/CY1124703T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284599A (en) | Methods and preparations for administration of iduronate-2-sulfatase to the central nervous system | |
PT3626258T (pt) | Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase | |
IL291556A (en) | Methods and preparations for administration of arylsulfatase a to the central nervous system | |
EP2588131A4 (en) | METHODS AND COMPOSITIONS FOR CNS ADMINISTRATION OF HEPARAN N-SULFATASE | |
EP2558120A4 (en) | METHOD AND COMPOSITION FOR INTRANASAL ADMINISTRATION | |
EP2588132A4 (en) | METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS | |
EP2635260A4 (en) | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | |
SG10201504913UA (en) | Compositions and methods for non-toxic delivery of antiprogestins | |
HK1254904B (zh) | 用於改變xlhed表型的組合物和方法 | |
EP2440192A4 (en) | COMPOSITIONS AND METHODS FOR ADMINISTERING MATERIALS | |
EP2437735A4 (en) | COMPOSITIONS AND METHODS FOR ADMINISTERING SUBSTANCES |